Afinitor

developed to target cancer cells to support tumour growth suppression.

Strengths: 5 · 10mg

developed to target cancer cells to support tumour growth suppression.

Strengths: 5 · 10mg

Where to Check Availability

Conditions: Renal Cell Carcinoma
Breast Cancer
Neuroendocrine Tumours
Therapeutic class: MTOR Inhibitor
Pharmacological class: Antineoplastic Agent
Contraindications: hypersensitivity to everolimus; hypersensitivity to sirolimus
Precautions and warnings: monitor blood glucose; risk of infection; regular blood count monitoring
Minor side effects: stomatitis; fatigue; rash
Moderate side effects: infections; pneumonitis; anaemia
Dosage forms: Tablet
Administration route: Oral use
Patient summary: developed to target cancer cells to support tumour growth suppression.
Prescription status: POM
Manufacturer: Novartis
Onset Time: varies per patient
Duration: 24 hours
Storage instructions: Store below 25°C. Protect from light.
Drug interactions: cytochrome p450 inhibitors; grapefruit
Pregnancy and breastfeeding: Pregnancy: must not be used. Breastfeeding: must not be used.

Serious side effects

interstitial lung disease — requires immediate medical attention; severe infections — requires immediate medical attention

Mechanism of action

Everolimus is a serine-threonine kinase inhibitor that acts as an mTOR inhibitor, reducing tumour cell proliferation and angiogenesis.

developed to target cancer cells to support tumour growth suppression.

Active ingredient(s): Everolimus
Listed indication(s): Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Tumours